Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive Subjects | Zendy

Joel E. Gallant | Zendy; Allan Rodríguez | Zendy; Winkler G. Weinberg | Zendy; Benjamin Young | Zendy; Daniel S Berger | Zendy; Michael L. Lim | Zendy; Qiming Liao | Zendy; Lisa Ross | Zendy; Judy Johnson | Zendy; Mark S. Shaefer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive Subjects

Author(s) -

Joel E. Gallant,

Allan Rodríguez,

Winkler G. Weinberg,

Benjamin Young,

Daniel S Berger,

Michael L. Lim,

Qiming Liao,

Lisa Ross,

Judy Johnson,

Mark S. Shaefer

Publication year - 2005

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/498069

Subject(s) - abacavir , lamivudine , virology , tenofovir , medicine , human immunodeficiency virus (hiv) , antiretroviral drug , antiretroviral treatment , reverse transcriptase inhibitor , sida , antiretroviral therapy , viral disease , viral load , virus , hepatitis b virus

Antiretroviral combinations that reduce the number of pills and dosing frequency have the potential to simplify therapy. We compared 2 regimens dosed as 2 pills once daily.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research